HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amon-Re Iguana sun care line with zinc oxide provides "immediate" protection.

This article was originally published in The Rose Sheet

Executive Summary

AMON-RE IGUANA SUN CARE LINE PROVIDES "IMMEDIATE" PROTECTION using a patent-pending silicone emulsifier system that delivers active sun-screen ingredients with "full SPF and waterproof protection on contact," according to the Thomasville, Ga.-based R&D firm. Amon-Re's branded entry into the sun care market uses a silicone technology that works in a manner similar to the volatile silicone technology found in transfer-resistant makeup, the company explained. The emulsion system, however, gives the products more "breathability" and flexibility with skin than is often found in transfer-resistant cosmetics, Amon-Re added. Shipping now to drug stores and supermarkets nationwide, the 15-SKU line includes Sport and Kids products, as well as a number of self-tanners.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel